Field-deployable viral diagnostics using CRISPR-Cas13.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 29700266.
- Also identified by DOI 10.1126/science.aas8836 and PMC identifier 6197056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mitigating global infectious disease requires diagnostic tools that are sensitive, specific, and rapidly field deployable. In this study, we demonstrate that the Cas13-based SHERLOCK (specific high-sensitivity enzymatic reporter unlocking) platform can detect Zika virus (ZIKV) and dengue virus (DENV) in patient samples at concentrations as low as 1 copy per microliter. We developed HUDSON (heating unextracted diagnostic samples to obliterate nucleases), a protocol that pairs with SHERLOCK for viral detection directly from bodily fluids, enabling instrument-free DENV detection directly from patient samples in <2 hours. We further demonstrate that SHERLOCK can distinguish the four DENV serotypes, as well as region-specific strains of ZIKV from the 2015-2016 pandemic. Finally, we report the rapid (<1 week) design and testing of instrument-free assays to detect clinically relevant viral single-nucleotide polymorphisms.
Medical subject headings
- Bacterial Proteins
- CRISPR-Associated Proteins
- Dengue
- Dengue Virus
- Endonucleases
- Enzyme Assays
- RNA, Viral
- Zika Virus
- Zika Virus Infection